June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Wet AMD recurrence rate in patients on 3 months interval anti-vegf therapy in a single community practice
Author Affiliations & Notes
  • Scott Oliver
    Ophthalmology, University of Colorado, Aurora, CO
  • Richard Yi-Jen Hwang
    Ophthalmology, University of Colorado, Aurora, CO
  • Footnotes
    Commercial Relationships Scott Oliver, None; Richard Hwang, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5381. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Scott Oliver, Richard Yi-Jen Hwang; Wet AMD recurrence rate in patients on 3 months interval anti-vegf therapy in a single community practice. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5381.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To determine wet AMD recurrence rate in patients on 3 months anti-vegf therapy in a single community practice.

Methods: A two year retrospective chart review of a single physician at a single practice of all wet AMD patients treated (ICD9 362.52) with anti-vegf therapy was performed. Patients were typically treated using a “treat and extend” methodology. Charts were evaluated for anti-vegf therapy, treatment interval, duration of treatment, trials off of anti-vegf therapy and AMD recurrence. AMD recurrence was defined as an increase in intra-retinal or subretinal fluid on OCT or presence of new subretinal retinal blood on exam per the physician’s evaluation. Patients on a 3 month interval treatment were defined as having no recurrence who have been extended to 3 months with at least one 3 month interval follow up while on anti-VEGF therapy.

Results: 321 wet AMD patients were seen over a two year interval from 2012 through 2014. 76 patients were on 3 month interval maintenance anti-vegf therapy. 9 of these patients were excluded based on incomplete data or follow up. The remaining 67 patients included 73 eyes on 3 month interval anti-vegf therapy of which 9 eyes had begun trials off of 3 month maintenance therapy. The remaining 64 eyes on 3 months interval treatments had an overall 14% recurrence of wet AMD (9/63) from 2012-2014. Mean interval of eyes on maintenance without recurrence (52/63=86%) was 64 +/- 7 (average +/- SEM) weeks and mean interval until recurrence was 93 +/- 24 weeks. Kaplan meier plot of data suggests a low rate of AMD recurrence rate within the first 3 years on maintenance therapy but an increased recurrence rate after 3 years.

Conclusions: Evaluation of a treat and extend methodology of treating wet AMD in this single community practice suggests that if a patient can be extended to 3 month intervals, there is a high relatively low chance of recurrence during the first 3 years on maintenance. Further data analysis are needed to identify factors related to recurrence.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.